Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | EEF2K | O00418 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671443 | 1.00 | KDM4E (0.55) | KDM4ECYP19A1EEF2KARALDH1A1 | |
| SCHEMBL3671445 | 1.00 | KDM4E (0.55) | KDM4ECYP19A1EEF2KARALDH1A1 | |
| SCHEMBL3676809 | 1.00 | KDM4E (0.55) | KDM4ECYP19A1EEF2KARALDH1A1 | |
| SCHEMBL5612911 | 0.87 | KDM4E (0.55) | KDM4ECYP19A1EEF2KARALDH1A1 | |
| SCHEMBL5709390 | 0.86 | THRB (0.49) | KDM4ECYP19A1ALDH1A1ALDH2LMNA | |
| SCHEMBL5709373 | 0.81 | SLC6A2 (0.39) | KDM4ECYP19A1ARHTTLMNA | |
| SCHEMBL14244628 | 0.81 | HTR1A (0.39) | KDM4ECYP19A1ARALDH1A1SIGMAR1 | |
| SCHEMBL29606711 | 0.81 | HTR1A (0.39) | KDM4ECYP19A1ARALDH1A1SIGMAR1 | |
| SCHEMBL14244391 | 0.81 | HTR1A (0.39) | KDM4ECYP19A1ARALDH1A1SIGMAR1 | |
| SCHEMBL6001645 | 0.81 | RAB9A (0.49) | KDM4EEEF2KALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2025-08-07 | — | — | US | disclosed |
| US-12116355-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2024-10-15 | — | — | US | disclosed |
| EP-4215512-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| EP-3508468-B1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2023-01-18 | — | — | EP | disclosed |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | KDM4E 4399/4885CYP19A1 2725/4885EEF2K 1725/4885 |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | KDM4E 4399/4885CYP19A1 2725/4885EEF2K 1725/4885 |
| US-12116355-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | KDM4E 4399/4885CYP19A1 2725/4885EEF2K 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.